Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) Shares Outstanding (Weighted Average) (2016 - 2025)

Veracyte's Shares Outstanding (Weighted Average) history spans 14 years, with the latest figure at $78.6 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 2.74% year-over-year to $78.6 million; the TTM value through Dec 2025 reached $78.6 million, up 2.74%, while the annual FY2025 figure was $78.6 million, 2.74% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $78.6 million at Veracyte, roughly flat from $78.4 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $78.6 million in Q4 2025 and bottomed at $63.3 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $72.5 million (2023), against an average of $72.9 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) soared 34.06% in 2021 before it grew 1.33% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $67.9 million in 2021, then increased by 5.39% to $71.5 million in 2022, then increased by 1.53% to $72.6 million in 2023, then rose by 5.29% to $76.5 million in 2024, then grew by 2.74% to $78.6 million in 2025.
  • Per Business Quant, the three most recent readings for VCYT's Shares Outstanding (Weighted Average) are $78.6 million (Q4 2025), $78.4 million (Q3 2025), and $78.2 million (Q2 2025).